We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment.
PURPOSE Despite recent improvements in supportive care , treatment-related death ( TRD ) remains a serious problem for lung cancer patients undergoing systemic chemotherapy .  However , few studies have formally assessed possible changes in the TRD rate over the past two decades . PATIENTS AND METHODS We search ed phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer ( NSCLC ) . Time trend was assessed using linear regression analysis . RESULTS The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms ( 46 477 patients ) , with information about the causes of deaths available for 197 arms ( 75 % , 30 147 patients ) .  Cisplatin-based regimens were the most frequently investigated . The crude TRD rate in the overall cohort of 119 trials was 1.26 % and has been notably consistent over the investigated time ( P = 0.762 ) . The most common cause of death was febrile neutropenia , with no significant change in its incidence over the years ( P = 0.139 ) . In contrast , deaths due to renal toxicity decreased significantly ( P = 0.042 ) , whereas deaths due to pulmonary disorder increased significantly ( P = 0.007 ) . Among the pharmacological agents investigated , docetaxel ( Taxotere ) and epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) were associated with relatively high rates of deaths from pulmonary disorders , but EGFR-TKIs were not associated with death from any other cause . CONCLUSIONS Despite of potential confounders in our results , the overall TRD rate has remained low , but not negligible , in phase III trials for advanced NSCLC , over the past two decades . Notably , the incidence and pattern of TRD stratified by cause have changed considerably
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV